LILLEY'S PHARMACOLOGY FOR CANADIAN HEALTH CARE PRACTICE 4TH EDITION
BY KARA SEALOCK|| COMPLETE TEST BANK GUIDE|| VERIFIED CHAPTERS
INCLUDED WITH ACCURATE & ELABORATED ANSWERS|| NEWEST UPDATE||
100% GURANTEED GUIDE
,Table of Contents
PART 1. PHARMACOLOGY BASICS ............................................................................................................... 4
CHAPTER 01: NURSING PRACTICE IN CANADA AND DRUG THERAPY .................................................... 4
CHAPTER 02: PHARMACOLOGICAL PRINCIPLES ...................................................................................... 8
CHAPTER 03: LEGAL AND ETHICAL CONSIDERATIONS .......................................................................... 13
CHAPTER 04: PATIENT-FOCUSED CONSIDERATIONS............................................................................. 18
CHAPTER 05: GENE THERAPY AND PHARMACOGENOMICS ................................................................. 26
CHAPTER 06: MEDICATION ERRORS: PREVENTING AND RESPONDING ............................................... 28
CHAPTER 07: PATIENT EDUCATION AND DRUG THERAPY .................................................................... 31
CHAPTER 08: OVER-THE-COUNTER DRUGS AND NATURAL HEALTH PRODUCTS ................................. 35
CHAPTER 09: VITAMINS AND MINERALS ............................................................................................... 39
CHAPTER 10: PRINCIPLES OF DRUG ADMINISTRATION ........................................................................ 43
PART 2. DRUGS AFFECTING THE CENTRAL NERVOUS SYSTEM ................................................................. 52
CHAPTER 11: ANALGESIC DRUGS ........................................................................................................... 52
CHAPTER 12: GENERAL AND LOCAL ANAESTHETICS ............................................................................. 58
CHAPTER 13: CENTRAL NERVOUS SYSTEM DEPRESSANTS AND MUSCLE RELAXANTS ........................ 62
CHAPTER 14: CENTRAL NERVOUS SYSTEM STIMULANTS AND RELATED DRUGS................................. 67
CHAPTER 15: ANTIEPILEPTIC DRUGS ..................................................................................................... 72
CHAPTER 16: ANTIPARKINSONIAN DRUGS ........................................................................................... 76
CHAPTER 17: PSYCHOTHERAPEUTIC DRUGS ......................................................................................... 81
CHAPTER 18: SUBSTANCE MISUSE ......................................................................................................... 87
PART 3. DRUGS AFFECTING THE AUTONOMIC NERVOUS SYSTEM .......................................................... 92
CHAPTER 19: ADRENERGIC DRUGS ........................................................................................................ 92
CHAPTER 20: ADRENERGIC-BLOCKING DRUGS ..................................................................................... 97
CHAPTER 21: CHOLINERGIC DRUGS ..................................................................................................... 102
CHAPTER 22: CHOLINERGIC-BLOCKING DRUGS................................................................................... 106
PART 4. DRUGS AFFECTING THE CARDIOVASCULAR AND RENAL SYSTEMS .......................................... 111
CHAPTER 23: ANTIHYPERTENSIVE DRUGS ........................................................................................... 111
CHAPTER 24: ANTIANGINAL DRUGS .................................................................................................... 116
CHAPTER 25: HEART FAILURE DRUGS .................................................................................................. 121
CHAPTER 26: ANTIDYSRHYTHMIC DRUGS ........................................................................................... 126
CHAPTER 27: COAGULATION MODIFIER DRUGS ................................................................................. 131
CHAPTER 28: ANTILIPEMIC DRUGS ...................................................................................................... 136
, CHAPTER 29: DIURETIC DRUGS ............................................................................................................ 142
CHAPTER 30: FLUIDS AND ELECTROLYTES ........................................................................................... 147
PART 5. DRUGS AFFECTING THE ENDOCRINE SYSTEM ............................................................................ 152
CHAPTER 31: PITUITARY DRUGS .......................................................................................................... 152
CHAPTER 32: THYROID AND ANTITHYROID DRUGS ............................................................................ 156
CHAPTER 33: ANTIDIABETIC DRUGS .................................................................................................... 161
CHAPTER 34: ADRENAL DRUGS............................................................................................................ 168
CHAPTER 35: WOMEN’S HEALTH DRUGS ............................................................................................ 172
CHAPTER 36: MEN’S HEALTH DRUGS................................................................................................... 179
PART 6. DRUGS AFFECTING THE RESPIRATORY SYSTEM ........................................................................ 184
CHAPTER 37: ANTIHISTAMINES, DECONGESTANTS, ANTITUSSIVES, AND EXPECTORANTS .............. 184
CHAPTER 38: RESPIRATORY DRUGS..................................................................................................... 188
PART 7. DRUGS AFFECTING THE GASTROINTESTINAL SYSTEM AND NUTRITION .................................. 193
CHAPTER 39: ACID-CONTROLLING DRUGS .......................................................................................... 193
CHAPTER 40: ANTIDIARRHEAL DRUGS AND LAXATIVES ..................................................................... 198
CHAPTER 41: ANTIEMETIC AND ANTINAUSEA DRUGS........................................................................ 203
CHAPTER 42: NUTRITIONAL SUPPLEMENTS ........................................................................................ 207
PART 8. ANTI-INFECTIVE AND ANTI-INFLAMMATORY DRUGS ............................................................... 211
CHAPTER 43: ANTIBIOTICS PART 1: SULFONAMIDES, PENICILLINS, CEPHALOSPORINS, MACROLIDES,
AND TETRACYCLINES ............................................................................................................................ 211
CHAPTER 44: ANTIBIOTICS PART 2: AMINOGLYCOSIDES, FLUOROQUINOLONES, AND OTHER DRUGS
.............................................................................................................................................................. 215
CHAPTER 45: ANTIVIRAL DRUGS.......................................................................................................... 219
CHAPTER 46: ANTITUBERCULAR DRUGS ............................................................................................. 225
CHAPTER 47: ANTIFUNGAL DRUGS ...................................................................................................... 229
CHAPTER 48: ANTIMALARIAL, ANTIPROTOZOAL, AND ANTHELMINTIC DRUGS ................................ 234
CHAPTER 49: ANTI-INFLAMMATORY AND ANTIGOUT DRUGS ........................................................... 238
PART 9. IMMUNE AND BIOLOGICAL MODIFIERS AND CHEMOTHERAPEUTIC DRUGS ........................... 243
CHAPTER 50: IMMUNOSUPPRESSANT DRUGS .................................................................................... 243
CHAPTER 51: IMMUNIZING DRUGS AND PANDEMIC PREPAREDNESS ............................................... 247
CHAPTER 52: ANTINEOPLASTIC DRUGS PART 1: CANCER OVERVIEW AND CELL CYCLE–SPECIFIC
DRUGS................................................................................................................................................... 251
CHAPTER 53: ANTINEOPLASTIC DRUGS PART 2: CELL CYCLE–NONSPECIFIC AND MISCELLANEOUS
DRUGS................................................................................................................................................... 255
, CHAPTER 54: BIOLOGICAL RESPONSE–MODIFYING DRUGS AND ANTIRHEUMATIC DRUGS ............. 258
PART 10. MISCELLANEOUS THERAPEUTICS: HEMATOLOGICAL, DERMATOLOGICAL, OPHTHALMIC, AND
OTIC DRUGS .............................................................................................................................................. 262
CHAPTER 55: ANEMIA DRUGS.............................................................................................................. 262
CHAPTER 56: DERMATOLOGICAL DRUGS ............................................................................................ 266
CHAPTER 57: OPHTHALMIC DRUGS ..................................................................................................... 271
CHAPTER 58: OTIC DRUGS.................................................................................................................... 275
PART 1. PHARMACOLOGY BASICS
CHAPTER 01: NURSING PRACTICE IN CANADA AND DRUG THERAPY
SEALOCK: LILLEY’S PHARMACOLOGY FOR CANADIAN HEALTH CARE PRACTICE, 4TH EDITION
MULTIPLE CHOICE
1. WHICH IS A JUDGEMENT ABOUT A PARTICULAR PATIENT’S POTENTIAL NEED OR PROBLEM?
A. A GOAL
B. AN ASSESSMENT
C. SUBJECTIVE DATA
D. A NURSING DIAGNOSIS
ACCURATE ANS>>D
NURSING DIAGNOSIS IS THE PHASE OF THE NURSING PROCESS DURING WHICH A CLINICAL JUDGEMENT
IS MADE ABOUT HOW A PATIENT RESPONDS TO HEATH CONDITIONS AND LIFE PROCESSES OR
VULNERABILITY FOR THAT RESPONSE.
DIF: COGNITIVE LEVEL: KNOWLEDGE
2. THE PATIENT IS TO RECEIVE ORAL FUROSEMIDE (LASIX) EVERY DAY; HOWEVER, BECAUSE THE
PATIENT IS UNABLE TO SWALLOW, HE CANNOT TAKE MEDICATION ORALLY, AS ORDERED. THE NURSE
NEEDS TO CONTACT THE PHYSICIAN. WHAT TYPE OF PROBLEM IS THIS?
A. A “RIGHT TIME” PROBLEM
B. A “RIGHT DOSE” PROBLEM
C. A “RIGHT ROUTE” PROBLEM
D. A “RIGHT MEDICATION” PROBLEM
,ACCURATE ANS>>C
THIS IS A “RIGHT ROUTE” PROBLEM: THE NURSE CANNOT ASSUME THE ROUTE AND MUST CLARIFY THE
ROUTE WITH THE PRESCRIBER. THIS IS NOT A “RIGHT TIME” PROBLEM BECAUSE THE ORDERED
FREQUENCY HAS NOT CHANGED. THIS IS NOT A “RIGHT DOSE” PROBLEM BECAUSE THE DOSE IS NOT
RELATED TO AN INABILITY TO SWALLOW. THIS IS NOT A “RIGHT MEDICATION” PROBLEM BECAUSE THE
MEDICATION ORDERED WILL NOT CHANGE, JUST THE ROUTE.
DIF: COGNITIVE LEVEL: APPLICATION
3. THE NURSE HAS BEEN MONITORING THE PATIENT’S PROGRESS ON HIS NEW DRUG REGIMEN
SINCE THE FIRST DOSE AND HAS BEEN DOCUMENTING SIGNS OF POSSIBLE ADVERSE EFFECTS. WHAT
NURSING PROCESS PHASE IS THE NURSE PRACTISING?
A. PLANNING
B. EVALUATION
C. IMPLEMENTATION
D. NURSING DIAGNOSIS
ACCURATE ANS>>B
MONITORING THE PATIENT’S PROGRESS IS PART OF THE EVALUATION PHASE. PLANNING,
IMPLEMENTATION, AND NURSING DIAGNOSIS ARE NOT ILLUSTRATED BY THIS EXAMPLE.
DIF: COGNITIVE LEVEL: APPLICATION
4. THE NURSE IS CARING FOR A PATIENT WHO HAS BEEN NEWLY DIAGNOSED WITH TYPE 1
DIABETES MELLITUS. WHICH STATEMENT BEST ILLUSTRATES AN OUTCOME CRITERION FOR THIS
PATIENT?
A. THE PATIENT WILL FOLLOW INSTRUCTIONS.
B. THE PATIENT WILL NOT EXPERIENCE COMPLICATIONS.
C. THE PATIENT ADHERES TO THE NEW INSULIN TREATMENT REGIMEN.
D. THE PATIENT DEMONSTRATES SAFE INSULIN SELF-ADMINISTRATION TECHNIQUE.
ACCURATE ANS>>D
HAVING THE PATIENT DEMONSTRATE SAFE INSULIN SELF-ADMINISTRATION TECHNIQUE IS A SPECIFIC
AND MEASURABLE OUTCOME CRITERION. FOLLOWING INSTRUCTIONS AND AVOIDING COMPLICATIONS
ARE NOT SPECIFIC CRITERIA. ADHERENCE TO THE NEW INSULIN TREATMENT REGIMEN IS NOT
OBJECTIVE AND WOULD BE DIFFICULT TO MEASURE.
DIF: COGNITIVE LEVEL: APPLICATION
, 5. WHICH ACTIVITY BEST REFLECTS THE IMPLEMENTATION PHASE OF THE NURSING PROCESS FOR
THE PATIENT WHO IS NEWLY DIAGNOSED WITH TYPE 1 DIABETES MELLITUS?
A. PROVIDING EDUCATION REGARDING SELF-INJECTION TECHNIQUE
B. SETTING GOALS AND OUTCOME CRITERIA WITH THE PATIENT’S INPUT
C. RECORDING A HISTORY OF OVER-THE-COUNTER MEDICATIONS USED AT HOME
D. FORMULATING NURSING DIAGNOSES REGARDING KNOWLEDGE DEFICITS RELATED TO THE NEW
TREATMENT REGIMEN
ACCURATE ANS>>A
EDUCATION IS AN INTERVENTION THAT OCCURS DURING THE IMPLEMENTATION PHASE. SETTING
GOALS AND OUTCOME CRITERIA REFLECTS THE PLANNING PHASE. RECORDING A DRUG HISTORY
REFLECTS THE ASSESSMENT PHASE. FORMULATING NURSING DIAGNOSES REGARDING A KNOWLEDGE
DEFICIT REFLECTS ANALYSIS OF DATA AS PART OF THE PLANNING PHASE.
DIF: COGNITIVE LEVEL: ANALYSIS
6. THE NURSE IS WORKING DURING A VERY BUSY NIGHT SHIFT, AND THE HEALTH CARE PROVIDER
HAS JUST GIVEN THE NURSE A MEDICATION ORDER OVER THE TELEPHONE, BUT THE NURSE DOES NOT
RECALL THE ROUTE. WHAT IS THE BEST WAY FOR THE NURSE TO AVOID MEDICATION ERRORS?
A. RECOPY THE ORDER NEATLY ON THE ORDER SHEET, WITH THE MOST COMMON ROUTE
INDICATED
B. CONSULT WITH THE PHARMACIST FOR CLARIFICATION ABOUT THE MOST COMMON ROUTE
C. CALL THE HEALTH CARE PROVIDER TO CLARIFY THE ROUTE OF ADMINISTRATION
D. WITHHOLD THE DRUG UNTIL THE HEALTH CARE PROVIDER VISITS THE PATIENT
ACCURATE ANS>>C
IF A MEDICATION ORDER DOES NOT INCLUDE THE ROUTE, THE NURSE MUST ASK THE HEALTH CARE
PROVIDER TO CLARIFY IT. NEVER ASSUME THE ROUTE OF ADMINISTRATION.
DIF: COGNITIVE LEVEL: APPLICATION | COGNITIVE LEVEL: ANALYSIS
7. WHICH CONSTITUTES THE TRADITIONAL FIVE RIGHTS OF MEDICATION ADMINISTRATION?
A. RIGHT DRUG, RIGHT ROUTE, RIGHT DOSE, RIGHT TIME, AND RIGHT PATIENT
B. RIGHT DRUG, THE RIGHT EFFECT, THE RIGHT ROUTE, THE RIGHT TIME, AND THE RIGHT PATIENT
C. RIGHT PATIENT, RIGHT STRENGTH, RIGHT DIAGNOSIS, RIGHT DRUG, AND RIGHT ROUTE
